Monday, December 8, 2014

Don't Doubt Acorda's Tenacity

Anyone who doubts Acorda's ACOR wisdom in buying Civitas or their ability to complete a successful phase III and launch of the levodopa inhaler product need only read the following article describing their tenacity in developing Ampyra. The same management team is in charge now.   Ampyra

No comments:

Post a Comment